SERUM sFas/sFasL RATIO IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IS A FUNCTION OF AGE

Turi, M.C.; D'Urbano, Marika; Celletti, Eleonora; Alessandri, Cristiano; Valesini, Guido; Paganelli, Roberto

doi:10.1016/j.archger.2009.09.032

Cited by 6 publications

(8 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The situation is even more complex since autoantibodies to FasL have been detected in sera of SLE patients which contribute to inhibit apoptotic cell death of lymphocytes (Suzuki et al, 1998). In our study (Turi et al, 2009) we confirmed that though slightly increased values of both sFas and sFasL are found in SLE patients compared to normal subjects, a very scattered distribution is observed. No definitive answer to the importance of these differences may derive from examining one factor when many contribute to the final effect, so we decided to derive and index from the ratio of the values of sFas to sFasL, which is about 50 in normal controls.…”

Section: Fas/fasl Dysregulation In Slesupporting

confidence: 78%

“…In our study (Turi et al, 2009) SLE patients with lower ratios of sFas/sFasL in their sera were of younger age, and had a shorter disease duration (as calculated by the time from diagnosis) and also shorter duration of therapy and/or less organ damage. This pointed to the association of the index with age, which resulted to be strongly correlated with this parameter.…”

Section: Role Of Fas/fasl In Slementioning

confidence: 97%

See 1 more Smart Citation

Fas Pathway of Cell Death and B Cell Dysregulation in SLE

Paganelli¹,

Paganelli²,

Turi³

2012

Systemic Lupus Erythematosus

View full text Add to dashboard Cite

Section: Fas/fasl Dysregulation In Slesupporting

confidence: 78%

Section: Role Of Fas/fasl In Slementioning

confidence: 97%

Fas Pathway of Cell Death and B Cell Dysregulation in SLE

Paganelli¹,

Paganelli²,

Turi³

2012

Systemic Lupus Erythematosus

View full text Add to dashboard Cite

“…Serum FasL concentrations have been shown to decrease with aging [29, 30], with higher serum FasL levels being associated with diseases related to imbalanced homeostasis of the immune cells [31–33]. As the follow-up results show, the most radical change in serum FasL levels in the present study had occurred by age 66, with the levels having decreased significantly by that age.…”

Section: Discussionsupporting

confidence: 45%

Declining Physical Performance Associates with Serum FasL, miR-21, and miR-146a in Aging Sprinters

Kangas

Törmäkangas

Heinonen

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Aging is associated with systemic inflammation and cellular apoptosis accelerating physiological dysfunctions. Whether physically active way of life affects these associations is unclear. This study measured the levels of serum inflammatory and apoptotic molecules, their change over 10 years, and their associations with physical performance in sprint-trained male athletes. HsCRP, cell counts, HGB, FasL, miR-21, and miR-146a were measured cross-sectionally (n = 67, 18–90 yrs) and serum FasL, miR-21, and miR-146a and their aging-related associations with physical performance were assessed over a 10-year follow-up (n = 49, 50–90 yrs). The cross-sectional study showed positive age correlations for neutrophils and negative for lymphocytes, red blood cells, HGB, FasL, and miR-146a. During the 10-year follow-up, FasL decreased (P = 0.017) and miR-21 (P < 0.001) and miR-146a (P = 0.005) levels increased. When combining the molecule levels, aging, and physical performance, FasL associated with countermovement jump and bench press (P < 0.001), miR-21 and miR-146a with knee flexion (P = 0.023; P < 0.001), and bench press (P = 0.004; P < 0.001) and miR-146a with sprint performance (P < 0.001). The studied serum molecules changed in an age-dependent manner and were associated with declining physical performance. They have potential as biomarkers of aging-related processes influencing the development of physiological dysfunctions. Further research is needed focusing on the origins and targets of circulating microRNAs to clarify their function in various tissues with aging.

show abstract

“…16 18 20 27 28 Fewer studies have focused on sFasL in SLE, although it has been reported to be elevated compared with HC in most studies. 21 23 26 29 A positive relationship between sFasL and SLE disease activity has been reported in one study, 26 but not in another. 30 In light of these discrepancies, measuring the ratio between sFas and sFasL may be of interest, since both proteins belong to the same immunological pathway and are able to modulate the Fas/FasL system.…”

mentioning

confidence: 94%

“…30 In light of these discrepancies, measuring the ratio between sFas and sFasL may be of interest, since both proteins belong to the same immunological pathway and are able to modulate the Fas/FasL system. 21 The use of this ratio may better reflect the Fas/FasL system biological activity as a whole, where sFas and sFasL may have divergent biological functions. 21 31 While the ratio has been investigated in other conditions, [32][33][34][35] only one prior study in a small cohort of 15 patients assessed this ratio in relation to SLE disease activity.…”

mentioning

confidence: 99%

Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus

et al. 2020

View full text Add to dashboard Cite

ObjectiveFas/Fas ligand (FasL) and B cell-activating factor (BAFF) signalling have pivotal roles in SLE pathogenesis. We investigated the clinical associations of serum concentrations of soluble Fas (sFas) and soluble FasL (sFasL) in SLE and their relationship with BAFF.MethodsSerum sFas and sFasL were quantified by multiplex assay, and BAFF by ELISA, in 118 patients with SLE and 17 healthy controls (HC). SLE disease activity and organ damage were assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and the Systemic Lupus International Collaborating Clinics Damage Index.ResultssFas, sFasL and BAFF were detectable in all samples. Serum sFas and sFasL were significantly higher in SLE compared with HC. In univariable regression analyses, patients with active renal disease and those with flare had significantly higher levels of sFas compared with those without. High serum BAFF in patients with SLE was associated with increased sFas but not sFasL. The association between sFas and renal disease remained significant after adjusting for BAFF, but the association with flare attenuated. High sFas levels were associated with increased time-adjusted mean SLEDAI-2K, even after adjusting for BAFF, and with higher odds of flare over time. In contrast, high sFasL was associated with reduced organ damage over time. Serum sFasL/sFas ratio was negatively associated with active overall disease, flare and organ damage.ConclusionsSerum sFas is associated with active renal SLE, and active disease and flare over time, while sFasL/sFas ratio is negatively associated with disease activity and organ damage accrual. Treatments correcting abnormal levels of sFas/FasL may be worthy of evaluation in SLE.

show abstract

SERUM sFas/sFasL RATIO IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IS A FUNCTION OF AGE

Cited by 6 publications

References 13 publications

Fas Pathway of Cell Death and B Cell Dysregulation in SLE

Fas Pathway of Cell Death and B Cell Dysregulation in SLE

Declining Physical Performance Associates with Serum FasL, miR-21, and miR-146a in Aging Sprinters

Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus

Contact Info

Product

Resources

About